To include your compound in the COVID-19 Resource Center, submit it here.

Verastem's duvelisib meets in Phase III for CLL

Verastem Inc. (NASDAQ:VSTM) reported top-line data from the Phase III DUO trial in 319 patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) showing that twice-daily 25 mg oral duvelisib

Read the full 353 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE